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The production of antibodies within the central nervous system (CNS) is a char-
acteristic finding in primary and postinfectious viral meningoencephalitis. Igs, par-
ticularly IgG, are increased in cerebrospinal fluid (CSF), and isoelectrofocusing of
CSF shows a series of so-called "oligoclonal" bands of IgG, which can be absorbed
by viral antigens (1, 2) . Furthermore, inflammatory cells in brain parenchyma and
meninges are composed of significant numbers ofB lymphocytes (3) . The mecha-
nisms leading to activation and differentiation of B cells within the CNS have not
been investigated so far. In general, B cell responses resultfrom.intercellular commu-
nications between B cells, T cells, and monocytes/macrophages . T-B cell cooperation
involves distinct T cell-derived helper factors such as IFN-y and B cell- stimulating
factor-2 (BSF2) (4) . BSF2, which has also been named IL-6, is identical to IFN-
02, as well as to the 26-kD factor (5) . In the present report, we demonstrate that
these cytokines are also produced within the CNS in viral meningitis and encepha-
litis . Synthesis ofBSF2 and IFN-y in the CNS may trigger generation of antiviral
antibodies by B lymphocytes/plasma cells having invaded the CNS in viral diseases .
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Materials and Methods
Brief Definitive Report
Mice.
￿
6-8-wk-old inbred C57B1/6 (H-2b) and outbred ICR +/+ and ICR nu/nu mice
ofeither sex were obtained from the breeding colony of the Institut fur Zuchthygiene, Tier-
spital Zurich, Switzerland .
Infection and Harvesting of Blood and Cerebrospinal Fluid.
￿
Animals were inoculated in-
tracerebrally with 100 plaque forming units ofLymphocytic choriomeningitis virus(LCMV)
Armstrong . On days indicated, CSF and serum was collected from the infected mice as de-
scribed (6) . CSF samples of 3-10 animals were pooled and used for determination ofBSF2
and IFN-y .
Asssayfor BSF-2 .
￿
The assay for BSF-2 was performed using the BSF2-dependent B cell
hybridoma 7TD1 (mouse-mouse) . Briefly, 7DT1 cells (kindly provided by Dr. J . van Snick,
Ludwig Institute for Cancer Research, Brussels, Belgium) were seeded in 96-well microtiter
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F-plates in Iscove's modified Dulbecco's medium supplemented with 10% FCS, 5 x 10-5 M
2-ME, 1.5MM L-glutamine, 0.24 MM L-asparagine, 0.55 MM L-arginine, and antibiotics
(7) . The cells were cultured at a density of 103 cells per well in the presence of serial dilu-
tions ofCSF or a highly purified standard containing 1,000 U/ml ofhuman BSF2 (5) (kindly
provided byDr. J . van Damme, Rega Institute for Medical Research, University ofLeuven,
Belgium) . For the final 16 h of the 3-d culture, the cells were pulsed with 1 EICi [3H]thymi-
dine (5 Ci/mmol) . 1 U ofBSF2 is defined as the amount ofBSF2 that results in half-maximal
thymidine incorporation in the assay . When using highly purified BSF2, the detection limit
of BSF2 was found to be 0.15 U/ml. When testing sera or CSF, the detection limit of the
BSF2 assay was 10 U/ml due to negative effects of the samples when being tested at concen-
trations>10% . To characterize the BSF2-like activity in CSF, a neutralizing goat anti-human
BSF2 antibody was used (5) (a generous gift ofDr. J . van Damme) . After a 3-h incubation
of the samples with the antibody (final dilution 1 :2,000) at 37°C, the residual activity was
determined in the assay.
ImmunoradiometricAssayforMurine IFN-y(MuIFN-y).
￿
MuIFN-y was measured by a solid-
phase, two-site "sandwich immunoassay" method (8) using the rat anti-MuIFN-y mAbs
R4-6A2 and AN-18 (kindly provided byDr. E . Havell, Trudeau Institute, Saranac Lake, NY,
and Dr. S. Landolfo, University of Turin, Turin, Italy) .
Human Cerebrospinal Fluids.
￿
Within the first 48 h of admission to the hospital, CSF samples
were collected from 19 patients ; 15 had aseptic viral meningitis and 4 had encephalitis due
to HSV 1 . Of these 19 patients with viral CNS disease, 9 patients were <20 yr old, 8 patients
were between 20 and 40, and 2 patients were >40 yr old. Furthermore, CSF were tested from
31 patients with multiple sclerosis and from the following 16 controls, which will be collec-
tively termed "other neurological diseases" (OND) : a group of non-inflammatory diseases
of the CNS, which was composed of two Alzheimer diseases, two syringomyelia, and one
amyotrophic lateral sclerosis . In addition, five patients with tension headache, four with disk
syndromes, and two with psychiatric disorders were included .
Results and Discussion
As shown previously, C5B1/6 mice intracerebrally infected withLCMV showed
onset of meningitis 6-7 d after infection and died 6-8 h later (6) . In CSF, white
blood cell pleocytosis occurred 6 d after infection, reaching 104 cells/ul on day 7 with
45% mononuclear cells . For measurement of cytokines, serum and CSF were col-
FIGURE 1 .
￿
Intrathecal synthesis ofBSF1
and IFN-y during viral infection of the
CNS. Serum (O) and CSF (") ofC57B1/6
mice infected with LCMV were inves-
tigated for BSF2 (A) and IFN-y (B) at
days indicated .FREI ET AL.
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TABLE I
BSF-2 and IFN-y in Athymic Mice with LCMV Infection
lected at progressivetimesduring infection. In the course ofLCMV disease, BSF2
was first detected in serum on day 1 and in CSF on day 2 (Fig. 1 A). Maximum
BSF2 levels were reachedafterrapidincrease from day4by day6; theconcentration
of BSF-2 was N60-fold higher in CSF compared with serum (Fig. 1 A).
In contrast to BSF2, no IFN-y was detected in the same CSF samples during the
first 4 d after infection (Fig. 1 B). After day 6 ofLCMV infection (the time point
pleocytosis in the CSF develops), a sharp increase in the levels of IFN-y was noted.
In serum, the amount of IFN--f gradually increased between day 2 and 5 (Fig. 1
B). However, the levels ofIFN-y were much higher in CSF compared with serum
(Fig. 1 B, Table I).
Athymic nu/nu mice infected intracerebrally with LCMV failed to develop menin-
gitis (9). When assessed in ICR nu/nu mice infected with LCMV, BSF2 was only
moderately increased both in serum and CSF. On day 5, the amount ofBSF2 was
N160- and -340-times lower when compared with the correspondingvalues in CSF
ofC5B1/6 and ICR +/+ mice, respectively (Fig. 1 A, Table I). In ICR +/+ mice,
maximum levels ofIFN-y were usually observed on day 6 at the time ofclinicalsigns
ofmeningitis. Table I showsthatin CSFofAhymicLCMVinfected ICRnu/numice,
IFN-y remained close to baseline levels. These findings in an animal model parallel
recent reports of IFN-y in human CSF during HSV1 encephalitis (10).
In CSF ofpatients with infectious CNS diseases, BSF2 was found in 12 of 15 pa-
tients with aseptic viral meningitis and in all of the four patients with encephalitis
due to HSV1 infection. In controls consisting of16 patientswith "other non-inflam-
matory neurological diseases" and of31 patients with multiple sclerosis, BSF2 was
detected only inone patientwithmultiple sclerosis (Fig. 2). Antibodies againsthuman
BSF2 completely neutralized the activity detected in viral meningitis and HSV1
encephalitis (datanot shown),indicatingthatthe hybridomagrowth-promoting effect
in these CSF is mediated by BSF-2.
The cellular source ofBSF2 in CSF is not known. Although originally described
as aT cell-derived factor (4), fibroblasts, monocytes, and endothelialcells have also
been found to secrete BSF2 (7, 11, 12). In a previous study on cachectin/TNFa
(aproduct ofactivated macrophages) it was not possible to identify cachectin/TNF
a in CSF of mice with LCMVinduced meningitis (6). In contrast, however, ca-
chectin/TNFa was present in CSF ofpatients with bacterial meningitis or ofmice
infected intracerebrally with Listeria monocytogenes (6). In viral meningitis, the
ICR +/+ ICR nu/nu
Days after BSF-2 IFN-y BSF-2 IFN-y
infection Serum CSF Serum CSF Serum CSF Serum CSF
U/ml U/ml
0 <10 <10 <0.01 <0.01 80 <10 <0 .01 <0 .01
1 120 <10 0.07 <0.01 270 <10 0 .15 1 .2
3 15 100 0.39 <0.01 900 <10 0.96 1 .3
5 530 85,000 1 .95 23 250 250 0.42 <0.01
6 1,500 36,000 1 .68 1,848 175 200 0.48 <0.01452
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FIGURE 2.
￿
BSF2 in CSFofpatients with asepticviral
meningitis and HSV1-induced encephalitis.
discrepancy between high level of BSF2 and absence of cachectin/TNFa in CSF
does not support the possibility ofBSF-2 beingproduced independent ofT cellsby
monocytes/macrophages in CNS. Becauseofconcomitant production ofBSF2 and
IFN-y, a Tcell-derived lymphokine, one may assume that BSF2 productionwithin
the CNS may depend on local infiltrating Tcells. This is further supported by the
observation ofonly minimal synthesis ofboth IFN-y and BSF2 in CNS ofLCMV
infected athymic ICR nu/nu mice. Production ofIFN-y has been shown to depend
on activation of mature T cells, which are deficient in nude mice.
The findings reported in this study may help to explain the synthesis ofantiviral
antibodies intheCNS during viral infections (1-3). IFN-yhas been shown tosyner-
gize with IL-1 and IL-2 in antigen-specific antibody production by B lymphocytes
(4). BSF2 supports the growth of B cell hybridomas and plasmocytomas (7) and
induces the final differentiationto high-rate Ig secretion ofpreactivated B cells (13).
Accordingly, BSF2 detected in CSF may contribute todifferentiation and secretion
ofantiviral antibodiesbypreactivated virus-specific B cells having invaded the CNS
in the course of viral infection.
Summary
Synthesis ofB cell-stimulating factor-2 (BSF-2) and IFN-y was shownin cerebro-
spinal fluids (CSF) collected from mice with experimental viral meningitis. In the
CSF, the level of BSF2 started to increase 24 h after intracerebral infection with
lymphocytic choriomeningitis virus (LCMV) with rapid increase afterday 4. IFN-y
was not detected in the CSF before day 5 or 6 afterinfection, but increased sharply
thereafter. Inathymicnudemice, LCMV infectiondid notresult inmeningitis, and
both BSF2 and IFN-y levels were only slightly and transiently elevated. These
findings suggest that activated mature Tcells are required for development ofdis-
ease and production ofboth BSF2 and IFN-y. As observed inmice, BSF2 was also
detected in 16 out of 19 CSF samples collected from patients with acute viral infec-
tions ofthe central nervous system (CNS). Intrathecal production ofBSF2 and IFN-yFREI ET AL.
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may be instrumental in local production of antiviral antibodies by B lympho-
cytes/plasma cells invading the CNS during viral CNS disease.
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Note added in proof: In a recent report by Houssiau et al. (14), they have also demonstrated
elevated levels of BSF2 in CSF of patients with viral brain diseases.
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